Michael Morabito
Stock Analyst at Chardan Capital
(n/a)
# 4,522
Out of 4,911 analysts
11
Total ratings
9.09%
Success rate
-28.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Morabito
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Maintains: Buy | $79 → $81 | $50.36 | +60.86% | 2 | Mar 17, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $202 → $203 | $300.99 | -32.56% | 2 | Feb 26, 2021 | |
| DRRX DURECT | Maintains: Buy | $70 → $80 | $0.55 | +14,429.60% | 2 | Feb 3, 2021 | |
| ETNB 89bio | Maintains: Buy | $59 → $95 | $9.65 | +884.46% | 3 | Sep 15, 2020 | |
| VKTX Viking Therapeutics | Maintains: Buy | $15 → $20 | $33.77 | -40.78% | 2 | Aug 31, 2020 |
Akero Therapeutics
Mar 17, 2021
Maintains: Buy
Price Target: $79 → $81
Current: $50.36
Upside: +60.86%
Madrigal Pharmaceuticals
Feb 26, 2021
Maintains: Buy
Price Target: $202 → $203
Current: $300.99
Upside: -32.56%
DURECT
Feb 3, 2021
Maintains: Buy
Price Target: $70 → $80
Current: $0.55
Upside: +14,429.60%
89bio
Sep 15, 2020
Maintains: Buy
Price Target: $59 → $95
Current: $9.65
Upside: +884.46%
Viking Therapeutics
Aug 31, 2020
Maintains: Buy
Price Target: $15 → $20
Current: $33.77
Upside: -40.78%